Fibrinogen Levels in Obese and Normal Individuals

Nath, Dinesh; Shivashekar, Meera; Vinodhini, V.

doi:10.7860/jcdr/2019/42041.13162

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…hsCRP is known to increase in hyperglycemia and is frequently used as a CVD and diabetes risk predictor 7 , 20 . The associations of hsCRP with hs-cTnT and fibrinogen may also support the involvement of inflammation in subclinical myocardial damage and CVD in the presence of insulin resistance and increased VAT 47 , 49 . Indeed, even after adjustment for BMI, body fat mass and, alternatively, waist-to-hip ratio, the condition of insulin resistance, rather than hyperglycemia, may predict increased fibrinogen levels in this group 49 .…”

Section: Discussionmentioning

confidence: 72%

“…Both hs-cTnT and fibrinogen associated with cholesterol/HDL and VAT, but not with each other, nor with HbA 1c —opposite to what was found in the Abnl-GT-β-cell failure group. The relationship between hs-cTnT and hyperlipidemia is known 45 , 46 and increased adiposity has been associated with increased inflammation and myocardial damage 47 . Thus, in this cross-sectional study, increased Cholesterol/HDL and VAT were the main factors contributing to the associations between increased myocardial strain, subclinical myocardial damage (hs-cTnT) and increased inflammation (hsCRP) in Abnl-GT-IR.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Africans in America study demonstrates that subclinical cardiovascular risk differs by etiology of abnormal glucose tolerance

Wentzel

Karera

Patterson

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Abnormal-glucose tolerance (Abnl-GT) is due to an imbalance between β-cell function and insulin resistance (IR) and is a major risk factor in cardiovascular disease (CVD). In sub-Saharan Africa, β-cell failure is emerging as an important cause of Abnl-GT (Abnl-GT-β-cell-failure). Visceral adipose tissue (VAT) volume and hyperlipidemia are major contributors to CVD risk when Abnl-GT is due to IR (Abnl-GT-IR). Yet, the CVD profile associated with Abnl-GT-β-cell failure is unknown. Therefore, our goals in 450 African-born Blacks (Male: 65%; Age: 39 ± 10 years; BMI 28 ± 5 kg/m2), living in America were to: (1) determine Abnl-GT prevalence and etiology; (2) assess by Abnl-GT etiology, associations between four understudied subclinical CVD risk factors in Africans: (a) subclinical myocardial damage (high-sensitivity troponin T (hs-cTnT)); (b) neurohormonal regulation (N-terminal pro-Brain-natriuretic peptide (NT-proBNP)); (c) coagulability (fibrinogen); (d) inflammation (high-sensitivity C-reactive protein (hsCRP)), as well as HbA1c, Cholesterol/HDL ratio and VAT. Glucose tolerance status was determined by the OGTT. IR was defined by the threshold at the lowest quartile for the Matsuda Index (≤ 2.97). Abnl-GT-IR required both Abnl-GT and IR. Abnl-GT-β-cell-failure was defined as Abnl-GT without IR. VAT was assessed by CT-scan. For both the Abnl-GT-β-cell-failure and Abnl-GT-IR groups, four multiple regression models were performed for hs-cTnT; NT-proBNP; fibrinogen and hsCRP, as dependent variables, with the remaining three biomarkers and HbA1c, Cholesterol/HDL and VAT as independent variables. Abnl-GT occurred in 38% (170/450). In the Abnl-GT group, β-cell failure occurred in 58% (98/170) and IR in 42% (72/170). VAT and Cholesterol/HDL were significantly lower in Abnl-GT-β-cell-failure group vs the Abnl-GT-IR group (both P < 0.001). In the Abnl-GT-β-cell-failure group: significant associations existed between hscTnT, fibrinogen, hs-CRP, and HbA1c (all P < 0.05), and none with Cholesterol/HDL or VAT. In Abnl-GT-IR: hs-cTnT, fibrinogen and hsCRP significantly associated with Cholesterol/HDL (all P < 0.05) and NT-proBNP inversely related to fibrinogen, hsCRP, HbA1c, Cholesterol/HDL, and VAT (all P < 0.05). The subclinical CVD risk profile differed between Abnl-GT-β-cell failure and Abnl-GT-IR. In Abnl-GT-β-cell failure subclinical CVD risk involved subclinical-myocardial damage, hypercoagulability and increased inflammation, but not hyperlipidemia or visceral adiposity. For Abnl-GT-IR, subclinical CVD risk related to subclinical myocardial damage, neurohormonal dysregulation, inflammation associated with hyperlipidemia and visceral adiposity. ClinicalTrials.gov Identifier: NCT00001853.

show abstract

Section: Discussionmentioning

confidence: 72%

Section: Discussionmentioning

confidence: 99%

The Africans in America study demonstrates that subclinical cardiovascular risk differs by etiology of abnormal glucose tolerance

Wentzel

Karera

Patterson

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Additionally, an increase in epinephrine and norepinephrine may have contributed, as these neurotransmitters are known to influence plasma FIB concentrations (Rezaimanesh & Amiri‐Farsani, 2011). Numerous studies have established a direct relationship between FIB and changes in body fat, body weight, and BMI (Nath et al., 2019).…”

Section: Discussionmentioning

confidence: 99%

The effect of 12 weeks of aerobic exercise training with or without saffron supplementation on diabetes‐specific markers and inflammation in women with type 2 diabetes: A randomized double‐blind placebo‐controlled trial

Rajabi,

Akbar Nezhad Gharehlo,

Madadizadeh

et al. 2024

European Journal of Sport Science

View full text Add to dashboard Cite

This study was conducted to investigate the effects of 12 weeks of aerobic exercise (AT) and saffron supplementation on hemostasis, inflammatory markers, and insulin resistance in obese women diagnosed with type 2 diabetes (T2D). A total of 44 women with T2D (mean age: 54.12 ± 5.63 years, mean BMI: 31.15 ± 1.50 kg/m2, HbA1c: 85 ± 4.2 mmol/mol) were included in a randomized, double‐blind, placebo‐controlled study. We were randomly assigned to one of four groups (n = 11 per group): saffron + training (ST), placebo + training (PT), saffron supplement (SS), and placebo (P). The ST and PT groups completed 12 weeks of AT (three sessions per week of mild to moderate intensity). The ST and SS groups were administered a daily dose of 200 mg of saffron powder for 12 weeks. Fasting blood samples were collected 48 h before the first AT session and/or nutritional supplementation and 48 h after the last AT session and/or nutritional supplementation. Post‐evaluation, homeostatic model assessment of insulin resistance value (HOMA‐IR, p < 0.001) and serum levels of glucose (p < 0.001), fibrinogen (FIB, p < 0.001), homocysteine (HCY, p < 0.001), interleukin‐6 (IL‐6, p < 0.001), and tumor necrosis factor α (TNFα, p < 0.001) showed significant reduction in the ST, PT, and SS groups compared to the P group (p < 0.05). In particular, the ST group showed a more significant reduction in all variables compared to the PT and SS groups (p < 0.05). Our results suggest that a 12‐week intervention with AT and saffron supplementation can independently improve markers related to hemostasis, inflammation, and insulin resistance. However, their combination showed the greatest effectiveness on the above markers.

show abstract

Fibrinogen Levels in Obese and Normal Individuals

Cited by 2 publications

References 0 publications

The Africans in America study demonstrates that subclinical cardiovascular risk differs by etiology of abnormal glucose tolerance

The Africans in America study demonstrates that subclinical cardiovascular risk differs by etiology of abnormal glucose tolerance

The effect of 12 weeks of aerobic exercise training with or without saffron supplementation on diabetes‐specific markers and inflammation in women with type 2 diabetes: A randomized double‐blind placebo‐controlled trial

Contact Info

Product

Resources

About